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Abstract
Background: The kallikrein-kinin system (KKS) is an endogenous pathway involved in angiogenesis and tumourigenesis, 
both vital for cancer growth and progression.
Objectives: To investigate the effect of  two bradykinin receptor (B1R and B2R) agonists on growth and motility of  prostate 
tumour (DU145) and micro-vascular endothelial cells (dMVECs).
Methods: Increasing concentrations of  selective B1R and B2R agonists were added to cultured cells.  Cell proliferation 
and migration were assessed using the 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) and modified 
Boyden Chamber assays, respectively.  Where significant stimulation was found, the influence of  an antagonist was also 
investigated. 
Results: Neither growth nor motility of  endothelial cells was affected by either agonist.  In DU145 cells, while the B2R 
agonist was without any significant effect, the B1R agonist stimulated proliferation and migration at concentrations of  10nM 
and 50nM respectively.  Further, this effect was abrogated when cells were pre-incubated with a B1R antagonist.
Conclusions: Unlike the physiologically-active B2R, the pathologically-inducible B1R may be implicated in prostate 
tumourigenic events.  The involvement of  the KKS in malignant prostate pathology supports on-going exploration of  
bradykinin receptor antagonists as target candidates in the development of  alternate approaches to cancer therapy.
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Introduction
The kallikrein-kinin system (KKS) consists of  two 
serine proteases, plasma and tissue kallikrein (TK), that 
release bio-active kinin peptides by enzymatic cleavage 
of  hepatically-derived kininogens 1.  Stimulation of  G 
protein-coupled bradykinin receptors (BR), B1R and 
B2R, mediate the effects of  bradykinin (BK), which 
include promotion of  cell growth, proliferation and
Corresponding author:
Naidoo S
Discipline of  Pharmaceutical Sciences,
School of  Health Sciences, Nelson R 
Mandela School of  Medicine campus, 
University of  KwaZulu-Natal, 
Private Bag X7, Congella 4013, Durban, 
South Africa.
Tel: +27 31 2604486
Fax: +27 31 2604338
Email: naidoot@ukzn.ac.za
migration 1-3.  Further, TK activates matrix metallo-
proteinases (MMPs) involved in extra-cellular matrix 
(ECM) degradation 4,5.
 The expression profiles of  TK and BK are 
altered in numerous human cancers, and several studies 
have implicated the KKS in growth and metastasis of  
prostate tumours: BK and BR agonists have been shown 
to stimulate proliferation, migration and invasion of  
PC3 prostate cancer cells in vitro 3,6,7, while some have 
reported that an interaction with both BR sub-types 
may be vital for the proliferation of  prostate cancer 
cells 6.  In addition, BR antagonist peptides have shown 
anti-cancer activity in athymic nude mice implanted 
with prostate cancer PC3 cells 8. 
 The KKS has been implicated in angiogenesis, 
the growth of  new blood vessels from the pre-existing 
vasculature 9,10.  Several studies have demonstrated a 
role for TK in neo-vascularisation following hind-limb 
ischemia in murine models 11-13.  The KKS may also be 
involved in tumour-associated angiogenesis, which is 
a pre-requisite for tumour growth and metastasis 14-16. 
The Ishihara group showed that a selective B2R, but 
not B1R, antagonist suppressed tumour-angiogenesis 
in mice implanted with sarcoma 180 cells 15.  They later 
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suggested that BK enhanced angiogenesis by promoting 
tumour vascular permeability16.  More recently TK, 
B1R and B2R have been shown to be present in the 
membrane projections of  both endothelial and prostate 
cancer cells in vitro 10.
 This study further explores the role of  the KKS 
in prostate cancer and angiogenesis by investigating 
the effect of  kinin receptor agonists and antagonists 
on prostate tumour (DU145) and micro-vascular 
endothelial (dMVEC) cell lines in vitro.
Methods
Ethics
Ethical approval was granted by the Biomedical 
Research Ethics Committee, University of  KwaZulu-
Natal (reference number BE152/08).
Cell Culture
 Micro-vascular endothelial cells (dMVECs) 
and prostate cancer (DU145) cells were obtained 
from Clonetics (BioWhittaker, Walkersville, USA) 
and Highveld Biological (Sandringham, South Africa) 
respectively. dMVECs and DU145 cells were cultured 
in endothelial basal medium (EBM-2) and Dulbecco’s 
Modified Eagle’s Medium (DMEM), respectively, as 
previously described 10. 
Agonists and Antagonists
 Selective B1R (Lys-Arg-Pro-Pro-Gly-Phe-Ser-
Pro-Phe) and B2R (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-
ψ(CH-NH)-Arg) agonists were commercially obtained 
from Tocris Bioscience, USA. These were added to both 
cell types in increasing concentrations to test their effect 
on proliferation and migration. Concentration ranges 
were 10 to 100nM for DU145 and 50 to 1000nM for 
dMVECs cells.  Pre-treatment with the B1R antagonist, 
des-Arg9-[Leu8]-BK acetate salt, at a concentration of  
10M, was used to test the specificity of  stimulation 
observed with the B1R agonist.  In addition, vascular 
endothelial growth factor (VEGF) was tested as a 
positive proliferation control.  BR antagonists and 
VEGF were purchased from Sigma-Aldrich, USA. 
Cell Proliferation
 The MTT assay was performed as previously 
described 17. Briefly, dMVEC and DU145 cells were 
seeded in 96-well culture plates (Corning, NY, USA) 
at a density of  4500 cells/cm2.  At 60% confluency, 
cell-specific growth medium was replaced with BR 
agonists or VEGF. For antagonist experiments, the B1R 
antagonist was added to cells 30 minutes prior to the 
addition of  agonists.  Cell proliferation was determined 
after 24 hours incubation at 37oC, 5% CO2 using the 
colorimetric MTT assay.  Each experiment was repeated 
a number of  times and four replicates were done for 
each sample.
Cell Migration
 Cell migration assays were performed using 
a modified Boyden chamber assay in 96-well HTS 
Transwell® plates (Corning) containing 8 µm polyester 
membranes.  Briefly, dMVEC or DU145 cells were 
re-suspended in their respective serum-free, growth 
factor-free medium and added to the upper chambers 
(20 000 cells/well).  BR agonists were prepared in 10% 
FBS/DMEM and 5% FBS/DMEM for dMVEC and 
DU145 migration assays, respectively, and added to the 
bottom chamber of  the modified Boyden chamber. 
For antagonist experiments, cells were pre-treated with 
10µM BR antagonist for 30 minutes before addition 
to the upper chambers.  The plate was incubated 
overnight at 37oC, 5% CO2. Cells that had migrated 
were then dissociated from the porous membrane and 
quantified following 1 hour incubation with 1x cell 
dissociation solution (CDS; Sigma, St. Louis, USA) and 
2mM fluorescent Calcein-AM working solution (BD 
Biosciences, USA) at a ratio of  1ml: 1µl.  The receiver 
plate was then read using a fluorescent top reader at 
485 nm excitation, 520nm emission (BMG, Germany). 
A standard curve was run concurrently with each 
experiment to extrapolate and quantify the number of  
cells that had migrated.  Each experiment was repeated 
a number of  times and three replicates were done for 
each sample.
Statistical Analysis
 One-way analysis of  variance (ANOVA) was 
used to test for statistical significance of  differences 
between multiple concentration groups followed by 
Dunnett’s post-hoc testing.  Student’s t-test was used for 
comparison between two groups.  A p-value ≤0.05 was 
considered statistically significant.  Statistical analysis 
was performed using the software package SPSS 18 
(IBM, USA).
Results
Addition of  the B1R agonist enhanced both proliferation 
and migration of  DU145 cells, the effect being 
statistically significant at 10 and 50nM respectively.  In 
addition, pre-treatment with a B1R antagonist abolished 
these effects (Figures 1a and 1b).  The B2R agonist 
produced a much smaller but non-significant effect on 
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growth and migration of  prostate tumour cells (Figures 
2a and 2b).
 In dMVECs, the B1R agonist produced a small 
(<6%) and statistically-insignificant proliferative effect 
at concentrations greater than 250nM (n=4, 4 replicates 
each), while the B2R agonist did not stimulate 
proliferation at any of  the concentrations tested 
(n=4, 4 replicates each). 
* p<0.05 
  n=6 (4 replicates each) 
1a 
1b 
Figure 1 (a).  Effect of  B1R agonist on DU145 proliferation.
In the absence and presence of  the B1R antagonist, a significant abrogation of  agonist-induced proliferation was 
demonstrated with B1R blocking, as indicated in the B1R agonist concentration range of  10 to 100nM. Agonist-
antagonist interaction was measured against a non-induced control.
Figure 1(b).  Effect of  B1R agonist on DU145 migration.
In the absence and presence of  B1R antagonist, it was demonstrated that the receptor blockade results in a 
reduction of  cell migration compared to both non-induced and agonist-induced cell motility.  Thus, there was 
significant induction of  cell migration at agonist concentrations of  10 and 50nM compared with non-induced 
controls, which were subsequently inhibited by the receptor antagonist.
Figure 2(a): DU145 proliferationin response to B2R agonist
The B2R receptor agonist had no effect on prostate tumour cell proliferation . 
Figure 2(b): DU145 migration in response to B2R agonist
The B2R receptor agonist had no effect on prostate tumour cell migration (b). 
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These results are shown in Figure 3.  In contrast to these 
findings, VEGF, a well-known mitogen, stimulated 
dMVEC proliferation.  Migration assays revealed that 
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Figure 3. Effect of  B1R and B2R agonists on dMVEC proliferation.
No effect was observed when either bradykinin receptor agonist was used to stimulate endothelial proliferation.
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Figure 4: dMVEC migration in response to B1R and B2R agonists 
No effects were observed when either bradykinin receptor agonist was used to stimulate endothelial cell 
migration.
Discussion
Our study supports a role for KKS in tumourigenesis: 
Addition of  a B1R agonist (Lys-Arg-Pro-Pro-Gly-Phe-
Ser-Pro-Phe) to cultured prostate cancer cells enhanced 
proliferation and migration, an effect that was also 
abrogated by the relevant antagonist.  Unlike Barki-
Harrington et al. 6 who found increased proliferation 
with stimulation of  the B2R, our study failed to show 
significant promotion of  tumour growth or motility 
with a B2R agonist (Arg-Pro-Pro-Gly-Phe-Ser-Pro-
Phe-ψ(CH-NH)-Arg).  However, this was not entirely 
unexpected because it is thought that the ubiquitous 
B2R mediates physiological effects while the inducible 
B1R plays a role in prostate cancer pathology 3.
 The extent to which the B1R agonist stimulated 
tumour cells in our study was less than that in previous 
work where 1.5 fold increases were noted 3,6.  However, 
this could be explained by the fact that both the 
prostate tumour cell line and BR agonists used in the 
studies were different.  DU145 and PC3 cell lines are 
both classical epithelial cell lines of  prostate cancer; 
however, they differ in terms of  their DNA profiles 
18.  The effect of  BR agonists on tumour cells in vitro 
may depend on several factors including the particular 
agonist and tumour type, and varying conditions of  
the experimental models.  The exposure period in our 
experiments was notably shorter (24 hours) than those 
in other studies (48 hours).
 In the present study, neither selective B1R nor 
B2R agonists induced proliferation of  micro-vascular 
endothelial cells (dMVECs).  This was in contrast to 
the findings in other studies implicating the KKS in 
angiogenesis.  For example, increased endothelial cell 
proliferation has been reported upon the addition of  a 
B1R, though not B2R, agonist 9,19.  Parenti et al. found 
that activation of  B1R was involved in endothelial 
cell proliferation, while B2R contributes indirectly to 
angiogenesis via mediation of  inflammatory processes 
20.  It is pertinent to note, however, that these studies 
used larger blood vessels such as human umbilical vein 
endothelial cells (HUVECs) and bovine coronary post-
capillary venules (CVEC).  In addition, exposure periods 
(48 and 72 hours) were far longer than the 24 hours in 
our study.  Interestingly, despite the difference in cell 
lines and conditions, our study supported the finding of  
Morbidelli et al. that BR agonists do not affect migration 
19.
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 In summary, this study, the first to investigate 
BR agonists and antagonists in DU145 tumourigenesis, 
supports previous authors who have suggested the 
involvement of  the KKS in prostate cancer.  The effect 
of  KKS may be less marked in DU145 cells than in 
those of  more aggressive and metastatic tumours such 
as PC3.
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